004310 — Hyundai Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for Hyundai Pharmaceutical Co, fiscal year end - November 30th, KRW millions except per share, conversion factor applied.

	2019 November 30th	2020 November 30th	2021 November 30th	2022 November 30th	2023 November 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS/A	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	134,650	132,966	139,803	162,690	180,763
Cost of Revenue
Gross Profit	63,684	58,322	56,313	68,837	76,593
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	133,877	129,913	143,872	154,735	186,584
Operating Profit	772	3,053	-4,069	7,955	-5,821
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,523	2,683	-4,021	5,670	8,034
Provision for Income Taxes
Net Income After Taxes	1,213	2,187	-3,173	-165	6,122
Net Income Before Extraordinary Items
Net Income	1,213	2,187	-3,173	-165	6,122
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	1,213	2,187	-3,173	-165	6,122
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	81.5	79.9	-55.6	-5.71	558
Dividends per Share